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Abstract: Docosahexaenoic acid (DHA) is a good source of fat that can be taken up through 
food, such as fish, or taken as a supplement. Evidence is building that DHA provides a high 
yield, low risk strategy to reduce preterm birth and/or low birth weight. These births are great 
costs to society. A recently completed phase III trial revealed that higher birth weight and 
gestational age were associated with DHA dosed at 600 mg/day. In this paper we take a posterior 
predictive approach to assess impacts of these findings on public health. Simple statistical 
models are not adequate for accurate posterior predictive distribution estimation. Of particular 
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weight and gestational age is well modeled by a finite mixture of three normal distributions. Data 
from our own clinical trial exhibit similar features. Using the mean and variance-covariance 
matrices from Schwartz et al. (2010) and flexible commensurate priors (Hobbs et al., 2012) for 
the mixing parameters, we estimate the effect of DHA supplementation on the over 20,000 
infants born in hospitals demographically similar to the hospital where the clinical trial was 
conducted.  
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Introduction 
 National hospital costs for infant admissions are much higher for preterm birth/low birth 
weight infants versus uncomplicated births (Russell et al., 2007). Using 2001 dollars, it is 
estimated that preterm (< 37 weeks gestation) or low birth weight (<2.5 kg) infants cost an 
average of $14,500 more and have, on average, hospital stays that are 11 days longer than for 
normal birth weight infants. Using a 3% annual escalation rate, the current relative cost is 
$20,071 per infant. The Institute of Medicine estimates the cost per infant born preterm to be 
$51,600, not including costs beyond early childhood (Behrman et al., 2006). Russell et al. (2007) 
report that the costs for preterm birth/low birth weight represent 47% of the costs for all infant 
stays and 27% for pediatric hospitalizations. Evidence of a cost effective solution to this medical 
problem has financial as well as public health implications. 
   Efforts to increase gestation and birth weight have medical and economic significance as 
well as significance for infant development. It is well known that low birth weight (<2.5 kg) and 
preterm birth (<37 weeks) contribute to poor developmental outcomes in infants (Hack et al., 
2002). Docosahexaenoic acid (DHA) is a good source of fat that can be taken up through food, 
such as fish, or taken as a supplement. Evidence is building that DHA provides a high yield, low 
risk strategy to reduce preterm birth and/or low birthweight. A recently completed phase III trial 
(called Kansas University DHA Outcomes Study, KUDOS) (Carlson et al., 2013) revealed that 
higher average birth weight and gestational age were associated with DHA supplementation of 
600 mg/day in the second and third trimesters (see also Helland et al., 2001; Makrides et al., 
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data to estimate the effects of cost-effectiveness of paying for the KUDOS level of DHA 
supplementation dosed at 600 mg/day. 
 The original KUDOS trial was powered using a one-sided two-sample t-test for the 
continuous variables gestational age and birth weight. The study was not powered for estimating 
differences in the categorical low birth weight and preterm birth. Therefore, to better estimate the 
implications of DHA, we utilize more sophisticated modeling and additional data sources beyond 
KUDOS outcomes, to improve the efficiency of estimating the effect of DHA on low birth 
weight and preterm birth. This paper extends both the medical and statistical literatures by: 
1. Providing statistically efficient estimates of the effect of paying for DHA for the 
estimated 20,000 newborn infants/year in demographically and geographically similar 
U.S. hospitals. This is articulated in a cost-effectiveness calculation in U.S. dollars 
invested per infant to reduce joint preterm (<37 weeks) and low birth weight (<2.5 kg). 
2. Extending the work of Peacock et al. (2012) that dichotomizes continuous data (<37 
weeks and <2.5 kg) but preserves the statistical power of its continuous parent. 
Specifically, we extend their methodology to include the important case of non-normal 
data (through the use of mixtures of multivariate normal distributions). 
3. Extending the work by Hobbs et al. (2012) to include commensurate priors for the case of 
a finite mixture of normal distributions. 
 A systematic review of the available evidence for DHA and related fish oil is presented in 
a Cochrane paper (Makrides, Duley, Olsen, 2012). In this paper results are shown for up to six 
trials for outcomes such as birthweight (<2.5 kg), preterm birth (<37 weeks), and early preterm 
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as being effective. Three trials were ongoing and one was not listed.  We did not use these 
studies in the current paper for two reasons: (1) the Cochrane study provides only cut-point data 
while we require raw data to fit the mixture model; and (2) the Cochrane data have different 
entry criteria and doses of DHA/fish oil, in general, than our study which was very broad with a 
specific dose of 600mg/day.  Our broad inclusion criteria and the registry data combined are 
much more appropriate for the inclusion in this paper. 
Data Sets 
KU Hospital Data from Five Years (Historical) 
The University of Kansas Hospital (KUH) recorded birth weights for infants during the 
same time period of the main clinical trial enrollment phase. This medical informatics project 
HERON (Waitman et al., 2011) has at least three clinical research functions: support 
retrospective studies, plan future studies, and build participant registries. We use the HERON 
rather innovatively to improve the prediction utility of the clinical trial. This historical data set is 
large as it contains n0=6,830 births at KUH between January 2006 and just before January 2011. 
We emphasize that gestational ages are currently not available in this database at this point. Few 
demographics are available; however among births reporting, 37% are black race and 44% are 
male, similar to the KUDOS data.  
KUDOS Data (Experimental) 
 During the same time (2006-2011) a Phase III randomized, double-blind, placebo-
controlled clinical trial compared supplements in n = 301 women (Carlson et al., 2013). 
Participants in the first group received placebo (n1= 147). The second group received 600 
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(DHA group is very similar), participant characteristics were reported as either averages with 
standard deviation (SD) or percentages: 46% were black race; 54% births male, the mean 
maternal age was 24.8 years (SD=4.7 years); 22% used an iron supplement; 38% smoked during 
pregnancy; and 2% reported drinking alcohol during pregnancy. Almost all of the mothers took 
prenatal supplements (99%), and had an average number of years of education of 13.4 years 
(SD=2.7), and a median income of $43,572 (SD=$19,201). The study was powered for two 
primary outcomes: birth weight and gestational age. Among the primary outcomes, a one-sided 
two-sample t-test indicated that compared to placebo, DHA had longer mean gestational age 
(2.87 days, p - value = 0.041) and increased mean birth weight (172 g, p-value = 0.004).  
North Carolina Detailed Birth Record (NCDBR) Database 
 To inform the structure of a mixture model (i.e., mixture of bivariate normal, three 
components), we use information from the NCDBR data that had 371,924 singleton births from 
2004-2006 (Schwartz et al., 2010). The investigators (Schwartz et al., 2010) specifically found 
that a mixture of three components of bivariate normal distributions is an excellent fit to the joint 
distribution of birth weight and gestational age. We will use the component means and 
covariances from this study. Specifically, for the multivariate formulation described above we 
specify component means as 
   ,           -,                                                                       (1) 
   ,           -  and                                                                                 (2) 
   ,           -                                                                              (3) 
Associated component covariance matrices are 
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   0
          
          
1  and                                                               (5) 
   0
           
          
1.                                                                           (6) 
The specific values of   ,   ,   ,   ,   , and    come from posterior estimates obtained from 
the three components discovered from the model of the birth registry data (Schwartz et al., 
2010). 
Historical Priors  
The use of historical priors in the design and analysis of clinical trials began with Pocock 
(1976). Chen and Ibrahim (2006) developed power priors that were later modified to obey the 
likelihood principle (Neuenschwander et al., 2009; Gajewski, 2010). Unfortunately, modified 
power priors borrow information too conservatively (Berry et al., 2010). To address this, Hobbs 
et al. (2011) and Hobbs et al. (2012) developed commensurate priors that offer pre-posterior 
admissible estimators for general and generalized mixed regression models. 
 Let’s first consider the two-sample design with one historical study (Hobbs et al., 2012). 
Let     (           ) represent n subjects such that      (  |     ), where di =0 or 1 
for patients in the control or treatment, respectively.   is the control’s parameter and ω is the 
additional treatment effect. The historical data are    (          ) such that 
      (   |  ). Let     (      ). The joint posterior of   given (    ) is proportional to 
       historical experimental 
 ( |      )   ( |     ⁄ ) (  )∏ (   |  )
  
   
∏ (  |     )
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Hobbs et al. (2012) refer to      (       ) as the commensurate prior, where τ is the 
“commensurability parameter.” Larger τ represents “increased commensurability” and induces 
increased borrowing of strength from the historical data.  
Commensurate Prior for Mixture of Normal Distributions 
In this section, we extend the commensurate prior model to the mixture of bivariate 
normal distributions.  
Historical Data Model 
 Let     be the joint variables for gestational age and birth weight of the j
th
 birth from the 
historical data. Specifically, let 
   |       (   |     )      (   |     )  (         ) (   |     ), 
where  (  |     ) is the multivariate normal pdf for k=1, 2, 3 and 
   (                     ) 
is the vector of mixing parameters. Recall, the mean and covariance for component   (     ) 
are derived from separate studies as detailed in Schwartz et al. (2010). While these parameters 
are fixed in our model, we allow the mix of the components to be unknown and modeled with 
the new datasets. Specifically, our implementation uses a parameterization of the mixing 
parameter of the form 
    
   (   )
∑    (   )
 
   
  
where we constrain      . Thus    (       ) is the two-vector parameter of interest. 
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 (    |  )  ∑
   (   )
∑    (   )
 
   
{ (   |     )   (   |     )+   (   |     )
 
   
  
Y0j in general contains birth weight and gestational age. However, our historical data only have 
birth weight, therefore after integrating missing gestational age, we only have the univariate birth 
weight y0j: 
 (   |  )  ∑
   (   )
∑    (   )
 
   
2 (   |  
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where   
( )
 and    
(   )
 represent the mean and variance for the k
th
 component’s birth weight. An 
attractive feature of this model is that we still gain a meaningful posterior distribution of    even 
without gestational age in the historical data.     
Experimental Data Model 
 Let Yi be the joint variables for gestational age and birth weight of the i
th
 birth from the 
clinical trial. Let θ be the parameter vector of mixture parameters for placebo and ω be the effect 
comparing placebo to DHA. Using the same logic as the historical model, we get the following 
model for the experimental data:  
 (  |   )  ∑
   (       )
∑    (       )
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To perform estimation we employ mixture parameters to mitigate the strength of 
borrowing from the historical data. Then the joint posterior distribution using the commensurate 
prior model is proportional to 
 (      |      )  
    ( |       * +
  ) (  ) ( )
  ∏{∑
   (   )
∑    (   )
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( )
   
(   )
/   .   |  
( )
   
(   )
/+
 
   
  
   
  (   |  
( )
   
(   )
/}
  ∏{∑
   (       )
∑    (       )
 
   
 
   
* (  |     )   (  |     )+
 
   
  (  |     )}             ( ) 
Consistent with Hobbs et al. (2012), we refer to   ( |       * +
  ) as the commensurate 
prior, and  (  ) as the initial prior, which we set to be proportional to unity. We also set 
 ( ) to be proportional to unity. The parameter vector τ represents the between-study precision, 
with larger values indicating increased commensurability and an increase in the borrowing of 
strength from the historical trial. 
In the next section we comprehensively describe the computational algorithms for the 
Bayesian implementation. Here we briefly describe the estimation of τ. Hobbs et al. (2012) point 
to a number of approaches for estimation, including empirical Bayes and full Bayes. They 
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et al. (2012) by adopting their gamma prior approach. This leads to a conditional posterior 
distribution for τ of  
 ( |        )   ∏  (  |   ̃      (      )
  ⁄    )
 
                              (8) 
where  ̃    is the prior estimate of   ;  and      is the confidence in that estimate, with 
smaller values representing less prior weight. Sparse versions of the prior structure can be 
incorporated as in Carvalho et al. (2010), and we consider other priors in the sensitivity analysis. 
Computation and Posterior Predictive Distributions 
 We employ standard successive substitution Markov chain Monte Carlo (MCMC) 
(Gelman et al., 2004). Specific to our implementation are multivariate versions of the Metropolis 
algorithm in two of the steps outlined in Appendix B. The other complete conditionals are of 
semi-conjugate form (Gelman et al., 2004). Inspection of mixing plots for all parameters 
indicates no reasonable contrary evidence of convergence to the stationary distribution after 
1,000 iterations; and we use the next 100,000 for inferential purposes. We select three different 
statistical values and calculate  ̂ (Gelman et al., 2004) and summarize it for each column of 
        and   (each of these has two vectors for a total of eight): 1.03, 1.00, 1.00, 1.01, 1.00, 
1.01, 1.01, and 1.00, respectively (all below the recommended 1.1). MATLAB code can be 
provided upon request. The form of the complete conditional distributions can be found in 
Appendix B. 
   In general, for the b
th
 iteration, MCMC provides us a straightforward calculation for 
anything we desire. Since we are interested in the joint probabilities of <2.5 kg and <37 weeks, 
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 (  |     ),           
where ( |     ) is the bivariate normal cumulative distribution function for k=1,2,3. 
For comparison purposes we calculate the posterior distribution that DHA has a lower risk than 
placebo control  (           ) which is estimated the proportion of times 
 (            | 
( )) is larger or equal to  (            | 
( )   ( )).  
Generally speaking, suppose we have the posterior distributions  |      and |    , 
and now desire the predictive distribution for the number of infants < 2.5 kg and < 37 weeks 
among the 20,000 regionally similar births. The “what if” scenario is as follows: how many 
infants would be at risk under placebo, and how many would be at risk under full DHA? Further, 
if there is a savings in the number of infants at risk, what would be the cost per infant taken out 
of the at risk category? Calling S the number of infants in the at risk category, we can get 
predictions under placebo and control for the b
th
 iteration: 
        
 ( )
     .       (            | 
( ))/, and                                     (9) 
    
 ( )
     .       (            | 
( )   ( ))/.                                 (10) 
All parameters are conditioned on the “data.” Note that for the “flat prior” case, we set   =0 
which says that Equations (11) and (12) are skipped in the MCMC shown in Appendix B, and 
the second part of Equation (13) (   ( |       * +
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We also perform a cost analysis that is a continuous function of the univariate gestational 
age.  For these purposes we take the simulated posterior parameters and simulate posterior 
predictive distributions of gestational age for placebo and control, which are  
          
 ( )
  ∑
   .  
( )
/
∑    .  
( )
/    
 
   2 (          
 |  
( )
   
(   )
/   (          
 |  
( )
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 (          
 |  
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(   )
/     and 
     
 ( )   ∑
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∑    .  
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( )
/    
 
   2 (     
 |  
( )   
(   )/   (     
 |  
( )   
(   ))+  
 (     
 |  
( )   
(   )/   (     
 |  
( )
   
(   )
/. 
We also respectively simulated 20,000 births for each iteration.  
Dichotomizing Continuous Data and Retaining Efficiency of Continuous Data 
 Dichotomizing continuous data is a huge problem because of the potential reduction in 
precision. For example, comparing the means from two normal distributions is statistically more 
powerful than dichotomizing these two continuous variables with a threshold and then 
comparing proportions (Peacock et al., 2012). Despite the reduced precision in the comparison of 
two proportions, clinicians prefer a threshold for clinical and policy decision making. Peacock et 
al. (2012) addressed this by using an approach that directly uses the integral of the normal 
distribution to get estimates of the proportions. It turns out that this approach preserves the 
precision of the original normal data. We describe their approach by supposing that in the 
continuous normal case, clinicians are interested in the proportion of infants under a certain 
threshold (e.g., < 2.5 kg). With this formulation there are two approaches to the problem. One is 
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for inference. Another approach is to estimate mean and variance parameters and plug them into 
a normal model, then integrate the normal model for an estimate of the proportion. Both 
approaches provide unbiased estimation, but the latter retains the statistical precision of the 
continuous model. In short, if the data are truly sufficiently normal, the Peacock approach out-
performs the dichotomous approach. We develop in this paper a non-normal extension to 
Peacock’s original normality assumption and apply it to our problem. 
Application 
 For an application of the commensurate prior approach, we present an analysis of the 
KUDOS data with the prior distributions derived from historical data. We first compare two 
models on the entire KUH (historical data only) population of n0=6,830 infants using posterior 
distributions. We first fit a traditional Beta-Binomial model on dichotomized data (<37 weeks 
and <2.5 kg) with a Beta(0,0) prior.  The probability of this event in the Beta-Binomial model is 
labeled     and the mixture model analog is      . The posterior mean for     and      is 
0.0814 and 0.0842 respectively. To assess the fitness of the model, we employ Bayesian model 
assessment of Gelman et al. (2004). In particular, we calculate a posterior predictive distribution 
using mix, then   , the predictive number of infants that are 2.5kg or less. The proportion of 










      /
 
, 
is calculated via simulation to be 0.5961, indicating a good fit of the model to the data. The mix 
approach is more efficient as the ratio of posterior variances of Beta (0.33%
2
) and mix (0.32%
2
) 
is 1.072. Thus, the Beta variance is 7.2% larger than that of mix. A comparison using an MCMC 
approach to mix with 100,000 draws results in the same posterior variance (.32%
2
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plot that overlaps the asymptotic normal approximation. Therefore, the 7.2% larger variance of 
Beta is not due to approximation or simulation error. 
Results 
 In Figure 1 we show the plots of placebo and DHA after fitting the mixture model. 
Zeroing in on the third component, where heights of the two figures are the same, tells us the 
impact in lowering the risk of joint preterm birth and low birth weight with placebo relative to 
DHA.  
Under the full commensurate prior model, the point estimates (posterior median) and 
95% credible intervals (CI) for the two components of    are 2.24 (2.13–2.34) and 1.34 (1.20–
1.48), respectively. For   the corresponding posterior median and 95% CIs are 2.27 (1.96–2.76) 
and 1.27 (0.0323–1.56) for the two components. The   (      )are (0.6150, 0.3108) for 
i=(1,2), indicating that the difference between the initial prior and posterior is not significant. 
Additional evidence for the lack of difference is contained in the estimation of the inverse of the 
square root of the precision ( √  ⁄ ), which are 0.10 (0.01–3.17) and 0.16 (0.01–6.91), 
respectively. Such posterior estimates suggest that component one is more commensurate than 
component two, since  (  )   (  ) (larger average commensurate parameters). We make 
this clearer with the joint probabilities of <2.5 kg and <37 weeks inference described in Table 1 
and their posterior densities in Figure 2. First, the Beta-binomial model shows that Pr(DHA ≥ 
Placebo)=0.0770 and the width of the 95% CIs are 0.0760 and 0.0529 for placebo and DHA 
respectively. Consistent with the results of the univariate model, the widths for the mixture-
model with flat priors drop to 0.0718 and 0.0474. The Pr(DHA ≥ Placebo)=0.0378, halving 
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The commensurability of the mixed model again enjoys efficiency gains as we see a drop in the 
interval width for placebo to 0.0398 but a slight increase in DHA to 0.0493. The overall Pr(DHA 
≥ Placebo) drops down to 0.0239.  
Figure 3 displays the posterior predictive distributions, along with 90% credible intervals 
(CIs), for 20,000 births in demographically (population) and geographically (Midwest) similar 
hospitals, with all mothers on either placebo or DHA. Under placebo, 1,341 (991–1,616) infants 
are predicted to be both preterm birth/low birth weight infants; whereas on DHA this drops to 
539 (235–1,410). The estimate of the difference between placebo and DHA is 782 (194–1,200). 
To estimate the cost on society to prevent one infant from being preterm birth/low birth weight, 
we can take the total cost and divide by this last difference estimate. From the public health 
impact perspective, the cost of 4,200mg/week (or 600 mg/day) for 24 weeks is about $183 
(http://www.enfamil.com/) per person. The cost to these hospitals for every mother (20,000) to 
obtain this dose would be $3.66 million/year. This DHA quote could drop with a negotiated 
global purchase. The cost effectiveness of a global DHA supplementation would be $4,680 
($3,050–$18,866) to prevent one infant from being both premature (<37 weeks) and born at low 
birth weight (<2.5 kg). Further, suppose the estimated cost differential was C for hospital stays. 
This cost-benefit analysis includes only the hospital stay costs and not the later development 
costs. Global hospital adoption of DHA in utero translates to a $3.66 million/year investment that 
saves 782C/year ($194C-$1200C/year) in infant medical costs. If the lower end of the interval 
$194C>$3.66 million, this translates into a good investment as long as C>$18, 866, which is 
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Cost Analysis as a Continuous Function of the Univariate Gestational Age  
In the previous section we assume a binary cost and consider a continuous cost function 
(a function of gestational age), based on a detailed cost analysis from California (Phibbs and 
Schmitt, 2006). The binary cost assumption might be very strong and may overstate the potential 
benefit of DHA supplementation. Furthermore, the binary cost setup ignores the rich continuous 
posterior information that the probability model provides. Fitting a least squares regression to the 
median cost as a function of gestational age provides us a 4
th







 + 4,000,000x – 30,000,000, where x is the gestational age in 
weeks and cost is in dollars, with cost=0 if x>37 weeks. As an example, births at 24 weeks cost 
an additional $300,000.  Evaluating the cost at the simulated 20,000 births and summing the 
costs for each of the placebo and DHA groups, we obtain posterior predictive distributions for 
placebo to be a mean of $70 million (90% CI: $52-$88 million); whereas for DHA this drops to a 
mean of $28 million ($9-$55 million).  This means that the lower 5%-tile estimate in cost per 
birth is $544.30, which is much greater than the $183 DHA cost per birth.     
Sensitivity Analysis 
 The results in this paper might be very dependent on the prior, and therefore we assess 
the sensitivity of our prior selection. Specifically we investigate nine models, each having a 
different prior. We use improper (flat) priors on the mixture weight parameters, which are found 
to be a proper posterior after inspection of the simulations. The resulting posterior, based on 
improper priors, is appropriate as the mean and covariance values of the components are spread 
out.  However, it is still necessary to assess the sensitivity of using improper priors. We approach 
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Specifically, the flat prior model (model 1) is changed to have components with independent 
priors, i.e. θk and ωk each with N(0,1/.001) (model 2), and is further changed to N(0,1/.01) for 
model 3. As shown in Table 2, the point estimates and 95% credible intervals do not change 
much across the first three models.  
 We also do not estimate the means and variances in the three-part mixture, rather we 
assume that these are fixed and known at particular values, based on an external database in a 
population that is not clearly exchangeable with the population of interest. We therefore compare 
our results using informative priors based on this external database, rather than assuming fixed 
values. To that end, in model 4 we loosen the restriction on the location parameter for the 
components, specifically       , where the means are listed in Equations (1)-(3), and the 
variance is diagonal and motivated from the 95% credible intervals listed in Schwartz et al. 
(2010).  Model 5 adds uncertainty to the variance-covariance parameters from Equations (4)-(6) 
by multiplying a constant ck~U(.95,1.05). The constant is further widened for model 6 such that 
ck ~U(.9,1.1).  This preserves positive definite for the variance-covariance parameters. Similarly, 
the point estimates and 95% credible intervals for models 4, 5, and 6 do not change much (Table 
2).   
 Once historical information is added, the models exhibit big changes in the posterior 
distribution as shown in Table 2. Models 7, 8, and 9 use the commensurate registry and see gains 
with narrower 95% credible intervals. Therefore we compare distributions within this set of 
models using various changes on the prior. With just one historical trial, the information on the 
commensurability parameter is limited since it is comparable to trying to estimate a standard 
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prior selected for   , the commensurability parameter, is a gamma distribution (model 7); 
however, in Hobbs et al. (2012) this prior is shown to exhibit less desirable borrowing properties 
than a sparsity-inducing prior, such as the spike-and-slab prior. Note that model 7 uses a 
Bayesian central limit theorem to approximate the likelihood for the historical part (see 
Appendix A).  We relax this in model 8 and use its full posterior.  The spike-and-slab prior is 
added for model 9. Specifically the prior for    assumes Pr(  <Sl)=0, Pr(  <u)=p0(u- Sl)/(Su - 
Sl), Sl≤u≤Su and Pr(  > Su)=Pr(  =K)=1-p0.  We define p0=.7, Sl =.05, Su =2, and K=40. For the 
placebo parameters, there are some slight variations on the 95% credible interval lengths with all 
exhibiting shorter lengths than the models without historical data (Table 2).   
Limitations 
 The main purpose of this paper is to efficiently measure the potential impact of 600 
mg/week of DHA to the cost savings of births in similar hospitals, where such a dose comes 
from one randomized clinical trial. We assume that the treatment effect in the randomized trial 
will be exactly the same as in clinical practice.  
 However, it is noted that the treatment effects would vary from study to study (which is 
why random-effects meta-analyses would be done if we had similar doses available). Future 
DHA studies will allow us to address this additional uncertainty. Related to such a random-
effects model, it is noted that the commensurate prior approach with one historical trial is similar 
to Pocock (1976), and to the meta-analytic-predictive approach (e.g., Spiegelhalter, Abrams, 
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Discussion and Conclusions 
 We first provide a fully Bayesian extension of commensurate prior models (Hobbs et al., 
2011; Hobbs et al., 2012) to include the mixture of distributions. The model is shown to increase 
efficiency in the case where the historical data and the current clinical trial commensurate. An 
added benefit is that we provide an extension of the work in Peacock et al. (2012) that 
dichotomizes continuous data but preserves the statistical power of its continuous parent, but for 
the non-normal case. However, the most important contribution of this paper is using this 
methodological improvement to gain efficient estimates of the potential impact that DHA 
supplementation has on society. Considering that premature and low birth weight infants can cost 
much more in medical costs, our results have shown that society paying for DHA is highly 
beneficial with high probability. 
 A concern might be with our assumption in the cost-benefit analysis where the births that 
are moved out of the at-risk category (low weight/preterm) have excess hospital costs that are, on 
average, equal to the average of all preterm/low weight births’ excess hospital costs. This 
assumption might be overly optimistic. If, for example, DHA exposure uniformly increases birth 
weights by 0.172 kg, the births that are moved out of the low weight category would be the ones 
whose counterfactual is close to the low/normal cutoff. Perhaps the births that would have been 
near 2.45 kg but moved up to 2.6 kg would incur nowhere near $20,000 less in hospital charges 
on average. In response to this we have reviewed our own KUH data. A recent query of the 
HERON database indicates that the rate of infants born in the calendar year 2008 with a length of 
stay of more than 7 days (to April 1, 2013) is 7/14 (95% CI:.27-.73) for infants less than 1.5 kg, 
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rate is 20/1446 (CI: .009-.021), clearly not overwhelming but trending towards differences in 
costs. 
 Future work includes looking at mixture models that incorporate estimation of the mean 
and covariance matrices of the mixture components. This was not necessary in our infant 
example but would be useful to generalize the approach to other applications. Extensions to the 
current approach are to include continuous covariates (e.g., dose) and incorporation of a meta 
analytic approach using other clinical trials  from  other countries with different doses of DHA 
but different baseline infant patterns, although this will require access to the raw birth weights 
and gestational ages in order to estimate the posterior distribution of the mixture parameters. We 
suggest a wide-spread supplementation rather than supplementation for a high-risk subpopulation 
only. Future work would be to identify higher-risk patients, which could improve the practical 
implications of our work. 
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Appendix A: Asymptotic Distribution 
 Bernardo and Smith (2007) derive posterior asymptotic normality. Adaptation of that 
approach leads to the following: as     ,   |    .  | ̂   ( ̂ )/, where  ̂  is the limiting 
posterior mode and  ( ̂ ) is the Fisher information evaluated at the limiting posterior mode. A 
direct application of this approach to our model finds 
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These elements of the Fisher information matrix lead directly to our result. Similar calculations 
provide   |      (  | ̂   ̂ 
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Appendix B: Complete Conditionals 
 We use MCMC to calculate the posterior distribution, which we programmed in 
MATLAB. This program requires complete conditional distributions (Gelman et al., 2004) to 
draw from the joint posterior distribution of all unknown parameters. As detailed below, we use 
multivariate implementations of the Metropolis algorithm in updating two sets of parameters. 
The other complete conditionals are of semi-conjugate (Gelman et al., 2004) form and are 
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Inspection of mixing plots (time series line plots) for all parameters indicates a convergence to 
the stationary distribution (joint posterior distribution) after 10,000 iterations; we then use the 
next 100, 000 for inferential purposes. For plotting purposes we use a kernel density estimator 
for continuous distributions and histograms for discrete distributions. The MATLAB code used 
can be obtained by contacting the first author. 
Using Equations (11)-(14), the complete conditionals for all the model parameters that 
provide the MCMC algorithm are  
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 MCMC sampling is detailed above with Equation 11 being a draw from a Gamma 
distribution. The complete conditional for    (Equation 12) is also simply drawn from a 
multivariate normal distribution, but requires some discussion. It combines the information from 
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a weighted average of the placebo parameter and the commensurate prior mean ( ̂ ). The higher 
the precision, the more weight goes towards the placebo parameter. This result is very similar to 
that found in Hobbs et al. (2012), Appendix A. Unlike previous literature, the conditional 
posteriors for the placebo and DHA parameters in Equations (13) and (14) are more complicated 
and do not have analytic forms. Therefore we use Metropolis algorithms (Gelman et al., 2004) to 
generate draws from them. We use variations of the multivariate distribution as a candidate draw 
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Figure 1. Three-dimensional plot of fitted mixture model for both placebo and DHA. Back two 
walls represent 2.5 kg and 37 weeks cutpoints. Zeroing in on the third component, heights on the 
two figures are the same tells us the impact in lowering the risk of joint preterm birth and low 
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Figure 2. Posterior distributions for the historical data, placebo, and DHA for probability a birth 
is < 2.5kg and < 37 weeks. 
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Figure 3. Posterior predictive distributions for the number of infants (S) at risk if they all took 
placebo versus all on DHA; and their differences. 
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Table 1. Inferential results and summaries based on simulated data for three models comparing 









Flat Prior  
 




Placebo DHA Placebo DHA Placebo DHA 
2.5%-tile 
 
0.031 0.010 0.034 0.010 0.043 0.010 
50%-tile 
 
0.062 0.029 0.064 0.027 0.067 0.027 
97.5%-tile 
 
0.107 0.063 0.105 0.058 0.083 0.059 
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Table 2. Results of sensitivity analyses after exploring various prior changes. 
Parameter Model 2.5%tile Median 97.5%tile Parameter 2.5%tile Median 97.5%tile 
ω1 1 -0.32 0.98 2.73 θ1 1.80 2.45 3.20 
 
2 -0.32 1.04 2.73  1.79 2.43 3.28 
 
3 -0.16 1.04 2.79  1.78 2.40 3.16 
 
4 -0.25 1.06 2.86  1.79 2.44 3.26 
 
5 -0.27 1.00 2.68  1.79 2.45 3.28 
 
6 -0.08 1.13 2.91  1.77 2.42 3.15 
 
7 -0.03 1.13 2.98  1.98 2.27 2.97 
 
8 0.11 1.12 2.76  2.00 2.27 2.83 
 
9 -0.12 1.04 2.60  1.95 2.36 3.06 
ω2 1 -0.52 1.26 3.47 θ2 -0.49 0.87 1.92 
 
2 -0.39 1.38 3.38  -0.54 0.83 1.91 
 
3 -0.26 1.43 3.62  -0.79 0.73 1.81 
 
4 -0.33 1.39 3.62  -0.60 0.83 1.90 
 
5 -0.35 1.32 3.37  -0.57 0.84 1.93 
 
6 -0.20 1.47 3.69  -0.58 0.77 1.81 
 
7 -0.53 0.89 2.98  0.39 1.28 1.61 
 
8 -0.39 0.97 3.06  -0.02 1.26 1.57 
 
9 -0.42 1.04 2.83  0.04 1.12 1.70 
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